Reporting bias in completed epilepsy intervention trials: A cross-sectional analysis

Epilepsy Research

Volumn 143, Issue , 2018, Pages 1-6

  Rayi, Appaji ^a,c   Thompson, Stephanie ^b   Gloss, David ^a   Malhotra, Konark ^a,c  

^a CHARLESTON AREA MEDICAL CENTER   (United States)

^b CAMC Health System   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

ClinicalTrials.gov; Epilepsy trials; Intervention; Reporting bias; Time lag bias

Indexed keywords

ARTICLE; CLINICAL STUDY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REPORTING BIAS; STATISTICAL BIAS; SYSTEMATIC REVIEW; TIME; UNITED STATES; CLINICAL TRIAL (TOPIC); CROSS-SECTIONAL STUDY; DRUG CONTROL; DRUG DATABASE; PUBLISHING;

CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; DATABASES, PHARMACEUTICAL; DRUG AND NARCOTIC CONTROL; EPILEPSY; HUMANS; PUBLICATION BIAS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85044713776     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2018.03.022     Document Type: Article

References (28)

1. Anderson, M.L., Chiswell, K., Peterson, E.D., Tasneem, A., Topping, J., Califf, R.M., Compliance with results reporting at ClinicalTrials.gov. N. Engl. J. Med. 372 (2015), 1031–1039, 10.1056/NEJMsa1409364.
2. ClinicalTrials.gov, 2017. Protocol Registration Data Element Definitions for Interventional and Observational Studies. URL https://prsinfo.clinicaltrials.gov/definitions.html (Accessed 12.8.17).
3. DeAngelis, C.D., Drazen, J.M., Frizelle, F.A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A.J.P.M., Schroeder, T.V., Sox, H.C., Van Der Weyden, M.B., Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA 292 (2004), 1363–1364, 10.1001/jama.292.11.1363.
4. Decullier, E., Lhéritier, V., Chapuis, F., Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ, 331, 2005, 19, 10.1136/bmj.38488.385995.8F.
5. Dickersin, K., Min, Y.I., NIH clinical trials and publication bias. Online J. Curr. Clin.Trials, 1993 Doc No 50, [4967 words; 53 paragraphs].
6. Dickersin, K., Reporting and Other Biases in Studies of Neurontin for Migraine, Psychiatric/bipolar Disorders, Nociceptive Pain, and Neuropathic Pain., 2008 URL https://www.industrydocumentslibrary.ucsf.edu/drug/docs/njhw0217 (Accessed 12.8.17).
7. Dirnagl, U., Lauritzen, M., Fighting publication bias: introducing the negative results section. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 30 (2010), 1263–1264, 10.1038/jcbfm.2010.51.
8. Dwan, K., Altman, D.G., Arnaiz, J.A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P.J., Von Elm, E., Gamble, C., Ghersi, D., Ioannidis, J.P.A., Simes, J., Williamson, P.R., Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One, 3, 2008, e3081, 10.1371/journal.pone.0003081.
9. Every-Palmer, S., Howick, J., How evidence-based medicine is failing due to biased trials and selective publication. J. Eval. Clin. Pract. 20 (2014), 908–914, 10.1111/jep.12147.
10. FDAAA, Food and Drug Administration Amendments Act of 2007. Public Law, 2007, 110–185 121 Stat.823.
11. Hartling, L., Craig, W.R., Russell, K., Stevens, K., Klassen, T.P., Factors influencing the publication of randomized controlled trials in child health research. Arch. Pediatr. Adolesc. Med. 158 (2004), 983–987, 10.1001/archpedi.158.10.983.
12. Hopewell, S., Loudon, K., Clarke, M.J., Oxman, A.D., Dickersin, K., Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst. Rev., 2009, MR000006, 10.1002/14651858 MR000006.pub3.
13. Knopman, D.K., Gross, R.A., A call for negative outcome studies. Neurology 82 (2014), 11–12, 10.1212/01.wnl.000043823378964.77.
14. Lampert, A., Hoffmann, G.F., Ries, M., Ten years after the International Committee of Medical Journal Editors’ clinical trial registration initiative, one quarter of phase 3 pediatric epilepsy clinical trials still remain unpublished: a cross sectional analysis. PLoS One, 11, 2016, e0144973, 10.1371/journal.pone.0144973.
15. Liebeskind, D.S., Kidwell, C.S., Sayre, J.W., Saver, J.L., Evidence of publication bias in reporting acute stroke clinical trials. Neurology, 67, 2006, 973, 10.1212/01.wnl.0000237331.16541.ac.
16. Malhotra, K., Rayi, A., Khunger, M., Thompson, S., Liebeskind, D.S., Reporting compliance of stroke trials: cross-sectional analysis. J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc. 26 (2017), 1472–1480, 10.1016/j.jstrokecerebrovasdis.2017.03.010.
17. Mechler, K., Hoffmann Georg, F., Dittmann Ralf, W., Ries, Markus, Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished—a cross-sectional analysis. Int. J. Methods Psychiatr. Res., 26, 2016, e1546, 10.1002/mpr.1546.
18. Melander, H., Ahlqvist-Rastad, J., Meijer, G., Beermann, B., Evidence b(i)ased medicine–selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326 (2003), 1171–1173, 10.1136/bmj.326.7400.1171.
19. Prayle, A.P., Hurley, M.N., Smyth, A.R., Compliance with mandatory reporting of clinical trial results on ClinicalTrials. gov: cross sectional study. BMJ, 2012, 344, 10.1136/bmj.d7373.
20. Schmidt, D., Galanopoulou Aristea, S., Mathern, Gary, Wang, Xuefeng, Why epilepsia open?. Epilepsia Open 1 (2016), 6–7, 10.1002/epi4.12007.
21. Stern, J.M., Simes, R.J., Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 315 (1997), 640–645.
22. Sterne, J.A., Egger, M., Moher, D., Addressing reporting biases. Higgins, J.P., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions, 2008, John Wiley & Sons, Ltd., Chichester, UK, 297–333, 10.1002/9780470712184.ch10.
23. Suñé P., Suñé J.M., Montoro, J.B., Positive outcomes influence the rate and time to publication, but not the impact factor of publications of clinical trial results. PLoS One, 8, 2013, e54583, 10.1371/journal.pone.0054583.
24. Turner, E.H., Matthews, A.M., Linardatos, E., Tell, R.A., Rosenthal, R., Selective publication of antidepressant trials and its influence on apparent efficacy. N. Engl. J. Med. 358 (2008), 252–260, 10.1056/NEJMsa065779.
25. Unger, J.M., Barlow, W.E., Ramsey, S.D., LeBlanc, M., Blanke, C.D., Hershman, D.L., The scientific impact of positive and negative phase 3 cancer clinical trials. JAMA Oncol. 2 (2016), 875–881, 10.1001/jamaoncol.2015.6487.
26. Vandenbroucke, J.P., von Elm, E., Altman, D.G., Gøtzsche, P.C., Mulrow, C.D., Pocock, S.J., Poole, C., Schlesselman, J.J., Egger, M., for the STROBE Initiative, Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med., 4, 2007, e297, 10.1371/journal.pmed.0040297.
27. Weber, E.J., Callaham, M.L., Wears, R.L., Barton, C., Young, G., Unpublished research from a medical specialty meeting: why investigators fail to publish. JAMA 280 (1998), 257–259.
28. Zarin, D.A., Tse, T., Williams, R.J., Carr, S., Trial reporting in ClinicalTrials.gov—the final rule. N. Engl. J. Med. 375 (2016), 1998–2004, 10.1056/NEJMsr1611785.